Values First Advisors Inc. Sells 4,895 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Values First Advisors Inc. lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 28,074 shares of the medical instruments supplier’s stock after selling 4,895 shares during the quarter. LeMaitre Vascular makes up approximately 1.4% of Values First Advisors Inc.’s investment portfolio, making the stock its 16th largest holding. Values First Advisors Inc.’s holdings in LeMaitre Vascular were worth $2,310,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. YHB Investment Advisors Inc. bought a new stake in LeMaitre Vascular during the 1st quarter valued at $36,000. SRS Capital Advisors Inc. increased its holdings in LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 524 shares during the period. GAMMA Investing LLC lifted its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares in the last quarter. SG Americas Securities LLC bought a new position in LeMaitre Vascular in the 2nd quarter valued at $177,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at $206,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on LMAT. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Monday, August 12th. JMP Securities boosted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Barrington Research lifted their target price on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $86.50.

Insider Activity

In other news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,251 shares of company stock valued at $3,714,994. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

LMAT traded up $1.16 during midday trading on Friday, hitting $84.75. The stock had a trading volume of 102,415 shares, compared to its average volume of 128,705. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $91.76. The business has a fifty day moving average of $83.43 and a 200 day moving average of $73.51. The company has a market cap of $1.90 billion, a P/E ratio of 56.13, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.37 EPS. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th will be issued a $0.16 dividend. The ex-dividend date is Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.76%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.